Could a single injection fix your aching back?
NCT ID NCT06144970
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-stage trial tests a new cell-based injection called TG-C for people with long-term lower back pain due to degenerative disc disease. 24 adults aged 22 to 70 will receive either a high, mid, or low dose of TG-C injected into the spinal disc, or a sham (fake) injection. The main goal is to check safety over 24 months, with pain levels also tracked.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
TG-C (a mixture of cells injected into the spinal disc)
What this could lead to
If safe and effective, this could point toward a non-surgical treatment for chronic back pain caused by worn-out discs.
What could go wrong
This is a very early Phase 1 trial with only 24 people, so it is primarily checking safety, not whether it works. The treatment involves injecting cells into the spine, which carries risks like infection or nerve damage.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DEGENERATIVE DISC DISEASE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••